-
STAT News – Biotech3 months agoSTAT+: Pharmalittle: We’re reading about Novo Nordisk boosting consumer focus, FDA approving a gene therapy, and more
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to...
-
Uncategorized3 months agoThis week in Drug Discovery (23 – 27 March)
News round-up for 23 – 27 March February by Bruno Quinney, Content Team at DDW. This week, obesity could be treated in other ways than through drugs suppressing appetite. Elsewhere, prostate cancer...
-
BioPharma Dive – AI / Data3 months ago
Rocket gene therapy cleared by FDA for rare immune disorder
Though the therapy, Kresladi, isn’t seen as a big seller, its clearance is a step forward for a company that’s lost most of its value since...
-
Endpoints News3 months ago
AstraZeneca’s in vivo CAR-T led to early responses, but one death in China trial
New clinical trial data on the in vivo CAR-T therapy that AstraZeneca acquired last year suggest that while the experimental treatment can curb multiple myeloma in...
-
Uncategorized3 months agoBeam reports positive data for genetic disease treatment
Biotechnology company Beam Therapeutics has reported encouraging data for its treatment for the genetic disease Alpha-1 Antitrypsin Deficiency (AATD). Beam announced BEAM-302, a liver-targeting lipid-nanoparticle (LNP) formulation...
-
Endpoints News3 months ago
Novartis to spend up to $2B on Excellergy and its next-gen Xolair candidate
With its blockbuster drug Xolair set to face biosimilar competition, Novartis said it will pay up to $2 billion in upfront and certain milestone payments to...
-
Uncategorized3 months agoFirst patient dosed in trial of Geographic Atrophy treatment
The first patient has been dosed in a first-in-human clinical trial of a treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). CTx001, developed...
-
Endpoints News3 months ago
Recursion appoints former Exelixis CMO; More executive moves at Incyte
→ Recursion has hired a new top doctor, bringing on Vicki Goodman as chief medical officer. Goodman previously served as CMO of the cancer biotechs Exelixis...
-
Endpoints News3 months ago
AstraZeneca’s COPD antibody gets Phase 3 wins in broader-than-expected population
AstraZeneca’s investigational antibody for chronic obstructive pulmonary disease has succeeded in two late-stage studies, despite having previously failed in a mid-stage trial. And, unexpectedly, the company...
-
GEN – Genetic Engineering & Biotechnology News3 months ago
Complete Genome Sequencing Reveals Malaria Mosquito Adapting to Insecticides
A sweeping population‑genomics effort has generated the first large collection of complete genomes for Anopheles darlingi, the dominant malaria vector across South America. The dataset—more than...
Amgen shores up Tavneos’ FDA defense with Duke data analysis
